Denali Therapeutics
About
Denali Therapeutics is a biopharmaceutical company focused on discovering, developing, and delivering medicines for people living with serious diseases, particularly neurodegenerative conditions. Their core strategy involves creating therapies that can effectively cross the blood-brain barrier using their proprietary Transport Vehicle (TV) technology. The company aims to address debilitating conditions such as Alzheimer's, Parkinson's, and ALS.
Key facts
At-a-glance profile data
- Website
- denalitherapeutics.com
- Headquarters
- South San Francisco, United States
- Founded
- 2015
- Total funding
- $1.0B (Royalty Funding)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 27 Mar 2026 | Royalty Funding | $200M | - |
| 27 Feb 2024 | Post IPO | $500M | - |
| 25 Aug 2016 | Series B | $130M | - |
| 14 May 2015 | Series A | $217M | - |
Tech stack
Detected on denalitherapeutics.com, last scanned 30 Aug 2026. Run your own scan
- Compliance
- GDPR, CCPA
- Frontend
- Tailwind CSS
- Analytics
- Segment
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Accessibility
- UserWay
Add first review
Frequently asked
How much funding has Denali Therapeutics raised?
Denali Therapeutics has raised a total of $1.0B in funding. The most recent round on record is Royalty Funding.